吉比特(603444.SH):3.5億元參投諾惟合悦基金 騰訊產業投資基金亦為LP
格隆匯12月31日丨吉比特(603444.SH)公佈,公司擬以有限合夥人身份出資3.5億元認購由廈門諾惟合悦企業管理合夥企業(有限合夥)(簡稱“諾惟合悦”)作為普通合夥人的廈門諾惟合悦創業投資合夥企業(有限合夥)(暫定名,以商事登記機關核准的名稱為準,簡稱“諾惟合悦基金”)份額。此次公司與諾惟合悦共同投資構成關聯交易。
諾惟合悦基金截至目前的認繳出資總額為7.72億元,其中,公司擬使用自有資金以有限合夥人身份認繳出資3.5億元,諾惟合悦擬以普通合夥人身份認繳出資400.00萬元,深圳市騰訊產業投資基金有限公司等其他有限合夥人合計認繳出資4.18億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.